Navigation Links
Beckman Coulter Announces Third Quarter 2007 Results
Date:10/30/2007

items including a tax settlement, reductions of certain foreign tax rates and additional R&D tax credits.

Net earnings were $60 million or $0.93 per fully diluted share. Adjusted net earnings were $49.5 million, or $0.77 per fully diluted share.

Recent Business Developments

-- Declared, in July, a $0.16 per share quarterly cash dividend, a $0.01

or 6.7% increase. This is the company's 73rd consecutive quarterly

dividend.

-- Re-purchased approximately 279,000 shares of Beckman Coulter stock at

an average price of $69.55 per share.

-- Signed a new agreement with Premier, Inc., the largest healthcare

alliance in the United States, for Beckman Coulter's offering of flow

cytometry instruments along with its core laboratory systems and

supplies.

-- Signed agreements with Amerinet, Inc., one of the nation's largest

healthcare group purchasing organizations, to provide a full range of

core laboratory systems and supplies.

-- Signed agreements with Johns Hopkins University, a leader in cancer

genomics research, that provide Beckman Coulter exclusive options to

license cancer genomics intellectual property that may arise from its

studies of multiple types of cancer including breast, colon and six

other cancers.

First Nine Months Summary

Through the first nine months of 2007, revenue increased 8.6%, or 6.8% in constant currency, over the prior year period. The acquisition of Lumigen contributed about 1% to this growth. Year-to-date 2007 consumables growth was 10.5%, or 8.8% in constant currency. The Lumigen contribution to consumables growth was 1.6%. Gross margin was 46.9% compared to 47.6% (adjusted) for the first nine months of 2006. Operating income increased by 22% and pretax profit increased by 74%; adjusting for special items, operating income increased by 10.1% and pretax profit increased by 12.9%. Adjusted
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... 16 Exiqon today announces,the adoption of the ... the company,s commitment to expanding its business to ... guide treatment,decisions in oncology., Exiqon is pleased ... for their,clinical laboratory diagnostics business, Exiqon Diagnostics. This,progressive ...
... Oct. 16 Gaining a first-cycle,approval for a ... $640,million in incremental revenue on average, according to ... of PAREXEL International (Nasdaq: PRXL ),and leading ... device industries. According to the PAREXEL Consulting,analysis, 60 ...
... of carbon nanotubessorted by centrifuge for lengthmaterials scientists ... (NIST) have made some of the most precise ... mats of nanotubes become transparent, conducting sheets. Their ... relatively homogeneousnot overly short, but uniform in length ...
Cached Biology Technology:Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 2Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc. 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 2PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 3PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 4PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average 5Paperwork: Buckypapers clarify electrical, optical behavior of nanotubes 2
(Date:4/23/2014)... transformed the energy landscape in the U.S., but ... among the energy industry, residents and agricultural interests ... that degraded water quality is a potential risk ... appears in the ACS journal Environmental Science ... colleagues point out that a major criticism of ...
(Date:4/23/2014)... or simply cli-fi, is a newly coined term for novels ... New research from University of Copenhagen shows how these fictions ... the potential consequences of climate change and imagine other living ... data on changes in the atmosphere; it is also a ... books we read and the films we see. And there ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... (May 23, 2008) A study led by Gregg ... Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, ... the direct thrombin inhibitor bivalirudin during primary angioplasty had ... rate of major bleeding, and a lower mortality rate ...
... May 22, Shire plc (LSE: SHP)(NASDAQ: SHPGY ... High Court approved,the scheme of arrangement between Shire ... The scheme, which becomes effective on 23 May ... Limited (LSE: SHP,NASDAQ: SHPGY) becoming the new holding ...
... international team of scientists surveying the waters of the ... has discovered for the first time high levels of ... raising concern for marine ecosystems from Canada to Mexico. ... research vessel, also discovered that this corrosive, acidified water ...
Cached Biology News:Findings released from 1 of the largest percutaneous coronary intervention trials ever 2Court Approves Scheme of Arrangement 2Court Approves Scheme of Arrangement 3Pacific coast turning more acidic 2Pacific coast turning more acidic 3
... When Ambion introduced the highly potent TURBO DNase ... new standard was set in DNA removal capabilities. ... DNase I that is much more efficient than ... amounts of unwanted DNA. TURBO DNase binds DNA ...
...
Lyophilized. Purity: ≥90% by electrophoresis. Reconstitute in 0.3% NaCl. Prepared from serum that has been shown by certified tests to be negative for HBsAg and for HIV and HCV antibodies. ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: